gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 03 Jul 2015.

Vascular endothelial growth factor A

vascular endothelial growth factor, VEGF, Vascular Endothelial Growth Factor A
This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: CAN, HAD, KDR, V1a, AGE
Papers using vascular endothelial growth factor antibodies
Podocyte vascular endothelial growth factor (Vegf164) overexpression causes severe nodular glomerulosclerosis in a mouse model of type I diabetes.
Chatziantoniou Christos, In PLoS ONE, 2010
... A shRNA targeting the first exon of mouse VEGF (Acc# M95200.1) was selected using siRNA Designer algorithm (Clontech).
Overexpression of von Hippel–Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice
El-Rifai Wael, In PLoS ONE, 2010
... Antibody against VEGF was acquired from Abcam Inc ...
Magnetic/silica nanocomposites as dual-mode contrast agents for combined magnetic resonance imaging and ultrasonography
Chen Yuh-Lien et al., In International Journal of Nanomedicine, 2010
... To bind the anti-VEGF Abs (sc507; Santa Cruz Biotechnology, Santa Cruz, CA) to ...
A thrombospondin-mimetic peptide, ABT-898, suppresses angiogenesis and promotes follicular atresia in pre- and early-antral follicles in vivo.
Addison Christina Lynn, In PLoS ONE, 2009
... Mouse anti-VEGF receptor 2 antibody was from Cell Signaling Technology ...
Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence
Fassnacht Martin et al., In Frontiers in Endocrinology, 2009
... Primary antibodies were VEGF-R2 monoclonal mouse antibody (Flk-1), used in a dilution of 1:250 and VEGF antibody A-20 in a dilution of 1:100 (both antibodies from Santa Cruz Biotechnology, Heidelberg, Germany) ...
more suppliers
Papers on vascular endothelial growth factor
Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis.
Baek et al., Seoul, South Korea. In Ann Surg Treat Res, 31 Jul 2015
The vascular endothelial growth factor (VEGF) and VEGF receptor pathway are recognized as the key regulators of the angiogenic process.
Antiangiogenic VEGF-Ax: A New Participant in Tumor Angiogenesis.
Fox et al., Bengaluru, India. In Cancer Res, 29 Jul 2015
UNASSIGNED: The transcript of the angiogenic factor vascular endothelial growth factor A (VEGF-A) is subject to a multitude of stimulus-dependent, posttranscriptional regulatory events, consistent with its unusually long 3' untranslated region.
Interactions between Osteopontin and Vascular Endothelial Growth Factor: Implications for Skeletal Disorders.
Weber et al., Cincinnati, United States. In Bone, 26 Jul 2015
UNASSIGNED: Osteopontin (OPN) and Vascular Endothelial Growth Factor (VEGF) are characterized by a convergence in function for maintaining the homeostasis of the skeletal and renal systems (the bone-renal-vascular axis regulates bone metabolism).
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
REACH Trial Investigators et al., Boston, United States. In Lancet Oncol, 18 Jul 2015
BACKGROUND: VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis.
Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research.
Sergiampietri et al., Pisa, Italy. In Crit Rev Oncol Hematol, 16 Jul 2015
UNASSIGNED: Vascular endothelial growth factor [VEGF] pathway, which plays a key role in angiogenesis, may be blocked by either extracellular interference with VEGF itself (bevacizumab [BEV] or aflibercept), or intracytoplasmic inhibition of VEGF receptor (pazopanib, nintedanib, cediranid, sunitinib and sorafenib).
Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.
Morrell et al., Basel, Switzerland. In Nat Med, 15 Jul 2015
Administration of BMP9 reversed established PAH in these mice, as well as in two other experimental PAH models, in which PAH develops in response to either monocrotaline or VEGF receptor inhibition combined with chronic hypoxia.
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma-A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
DiPaola et al., Philadelphia, United States. In J Clin Oncol, 15 Jul 2015
PURPOSE: On the basis of evidence that resistance to vascular endothelial growth factor (VEGF) receptor inhibition is caused by hypoxia-driven residual VEGF and other proangiogenic factors, combinations of agents from these classes were hypothesized to improve treatment outcomes relative to single-agent VEGF pathway blockade.
A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain.
Kuner et al., Heidelberg, Germany. In Cancer Cell, 08 Jul 2015
Here, we report a non-vascular role for ligands of the Vascular Endothelial Growth Factor (VEGF) family in cancer pain.
[Advance in the biology of pancreatic of cancer].
Cordelier et al., Toulouse, France. In Bull Cancer, 30 Jun 2015
At a late stage of tumor development, an increase of telomerase activity, an over expression of growth factors and/or their receptors (EGF, Nerve Growth Factor, gastrin), of pro-angiogenic factors (VEGF, FGF, PDGF), of invasiveness factors (metalloproteinases, tissue plasminogen activators) occurs.
Single-cell transcriptome analyses reveal signals to activate dormant neural stem cells.
Li et al., Shanghai, China. In Cell, 21 Jun 2015
Administration of vascular endothelial growth factor (VEGF) activated CD133(+) ependymal neural stem cells (NSCs), lining not only the lateral but also the fourth ventricles and, together with basic fibroblast growth factor (bFGF), elicited subsequent neural lineage differentiation and migration.
Allogeneic Mesenchymal Stem Cells Restore Endothelial Function in Heart Failure by Stimulating Endothelial Progenitor Cells.
Hare et al., Miami, United States. In Ebiomedicine, May 2015
We assessed EPC-colony forming units (EPC-CFUs), FMD, and circulating levels of vascular endothelial growth factor (VEGF) in patients before and three months after MSC transendocardial injection (n = 22) and in healthy controls (n = 10).
MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation.
Ashkenazi et al., San Francisco, United States. In Ebiomedicine, May 2015
UNASSIGNED: Hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) drive cancer through their respective receptors, MET and VEGF receptor 2 (VEGFR2).
Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells.
Bazhin et al., Heidelberg, Germany. In Oncoimmunology, Apr 2015
While DC and macrophages seem not to play a significant role in this PDAC model in the context of immunosuppression, MDSC are highly suppressive, and their accumulation is associated with an increase in intratumoral VEGF concentration during the PDAC progression.
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.
Beckhove et al., Heidelberg, Germany. In Oncoimmunology, Apr 2015
We furthermore observed a significant reduction of tumor perfusion after 38 d in vaccinated patients together with increased levels of serum biomarkers indicative of anti-angiogenic activity, VEGF-A, and collagen IV.
A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer.
Kumar et al., United Kingdom. In Ebiomedicine, Jan 2015
Secondary immunohistochemical outcomes assessed these tumour markers: VEGF, EGFR, c-MYC, CD31, Ki67 and p53, and clinical responses.
Circulating endothelial progenitor cells are reduced in rat oxygen-induced retinopathy despite a retinal SDF-1/CXCR4 and VEGF proangiogenic response.
Fernández-Durango et al., Madrid, Spain. In Life Sci, 2012
We found increased levels of CXCR4 and VEGF mRNA in OIR retinas, especially during the vascular attenuation stage
Vascular endothelial growth factor-induced osteopontin expression mediates vascular inflammation and neointima formation via Flt-1 in adventitial fibroblasts.
Gao et al., Shanghai, China. In Arterioscler Thromb Vasc Biol, 2012
VEGF/Flt-1 signaling plays a significant role in vascular inflammation and neointima formation by regulating osteopontin expression in vascular adevntitial fibroblasts.
Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation.
Olsen et al., Boston, United States. In J Clin Invest, 2012
VEGF controls differentiation in mesenchymal stem cells by regulating the transcription factors RUNX2 and PPARgamma2 as well as through a reciprocal interaction with nuclear envelope proteins lamin A and C.
Current evidence on VEGF+405G/C polymorphism and malignancy susceptibility: a meta-analysis involving 30 studies.
Zhang et al., Nanning, China. In Twin Res Hum Genet, 2012
Our meta-analysis indicated a weak association of VEGF+405G/C polymorphism with malignancy susceptibility in Africans, no persuasive evidence of association between the polymorphism and malignancy susceptibility was detected in the pooled analyses.
Quantification of tumour and circulating vascular endothelial growth factor (VEGF) in patients with oesophagogastric cancer: a long-term follow-up study.
Spence et al., United Kingdom. In Br J Biomed Sci, 2011
analysis of tumour and circulating vascular endothelial growth factor (VEGF) in patients with oesophagogastric cancer
More papers using vascular endothelial growth factor antibodies
Magnetically enhanced high-specificity virus detection using bio-activated magnetic nanoparticles with antibodies as labeling markers
Yang Hong-Chang et al., In International Journal of Nanomedicine, 2009
... MO), conjugated bilirubin (C-BL) (14370-250MG; Sigma), triglyceride (TG) (T2449-10ML, Sigma), and vascular endothelial growth factor (VEGF) (sc-7269; Santa Cruz Biotechnology, Santa Cruz, CA), were ...
Endothelial precursors in vascular repair
Wu Zhongshi et al., In International Journal of Nanomedicine, 2009
... Human recombinant VEGF-165 was purchased from Cell Signaling technology (Danvers, MA) ...
Gambogic acid inhibits angiogenesis through suppressing vascular endothelial growth factor-induced tyrosine phosphorylation of KDR/Flk-1
Chen Baoan et al., In International Journal of Nanomedicine, 2006
... Monoclonal antibodies, including ETS1, cyclin D1, u-PA, and VEGF, were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) ...
Reducible poly(amido ethylenimine) directed to enhance RNA interference
Zhang Qiang et al., In International Journal of Nanomedicine, 2006
... Human VEGF ELISA Kit was purchased from RayBiotech, Inc (Norcross, GA).
Increased lymphangiogenesis in joints of mice with inflammatory arthritis
Detmar Michael et al., In The Journal of Experimental Medicine, 2006
... Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice ...
The Tol2kit: A multisite gateway-based construction kit for Tol2 transposon transgenesis constructs
Jin Suk-Won et al., In Nature cell biology, 2006
... Hyperplasia of lymphatic vessels in VEGF-C transgenic mice ...
Aminopeptidase N/CD13 induces angiogenesis through interaction with a pro-angiogenic protein, galectin-3
Panjwani Noorjahan et al., In The Journal of Experimental Medicine, 2006
... Recombinant VEGF-A was obtained from Cell Sciences and R&D Systems ...
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster.
Oshima Robert, In PLoS ONE, 2005
... antibodies for phosphor-H2AX, Ser 139, (γH2AX) (BioLegend, San Diego, CA, USA), vascular endothelial growth factor (VEGF, Santa Cruz Biotechnology), thrombospondin -1 (TSP-1) (Lab ...
A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration
Opal Puneet et al., In Nature Medicine, 2005
... provided and characterized the VEGF transgenic mice ...
Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor (VEGF) expression
Tombran-Tink Joyce et al., In Journal of Ocular Biology, Diseases, and Informatics, 2005
... After this blocking step, slides were incubated for 2 h with rabbit polyclonal antibody directed against VEGF (Santa Cruz Biotechnology, Santa Cruz, CA, USA) ...
Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt–β-catenin and Wnt–RhoA–Rac1 pathways
Rabinovitch Marlene et al., In The Journal of Cell Biology, 2000
... Anti-VEGF and antisurvivin were obtained from Abcam.
QSAR study on the contribution of log P and Es to the in vitro antiprotozoal activity of glutathione derivatives
Gaffney John et al., In BMC Cell Biology, 2000
... from Apollo Cytokine Research, (Cambridge, UK), EGF, VEGFR-1 and -2, FGFR-1 and -2, anti-FGF-2 and anti-VEGF antibodies were obtained from Santa Cruz Biotechnology (Heidelberg, GDR) ...
Fibroblast growth factor 2 control of vascular tone
Mignatti Paolo et al., In The Journal of Cell Biology, 1997
... (Minneapolis, MN); anti-human VEGF antibody (αVEGF sc507) was purchased from Santa Cruz Biotechnology, Inc. ...
VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis
Detmar Michael et al., In The Journal of Experimental Medicine, 1997
... Generation of K14/GFP and of K14/GFP/VEGF-A transgenic mice.
New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay.
Ng Irene Oi-Lin, In PLoS ONE, 1996
... (goat polyclonal, Santa Cruz, Santa Cruz, CA, USA), anti-Laminin mAb (Biogenex, San Ramon, CA, USA), anti-VEGF-C mAb (Zymed, San Francisco, CA, USA), or anti- IL6 (rabbit polyclonal, Abcam, Cambridge, UK) ...
Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c–dependent activation of caspase-3
He Shaoheng et al., In International Journal of Molecular Sciences, 1996
... antibody was purchased from ProSci Incorporated (Poway, CA, USA), rabbit anti-human vascular endothelial growth factor (VEGF) polyclonal antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA), ...
Pharmacology of oleanolic acid and ursolic acid.
Bauer Joseph Alan, In PLoS ONE, 1994
... Antibodies against Bax (clone P-19), VEGF (clone C-1) and tubulin (clone b-7) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) ...
Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture.
Emanueli Costanza, In PLoS ONE, 1993
... The responder tet-soluble VEGF-R1 transgenic line encodes a tetracycline-inducible protein ...
share on facebooktweetadd +1mail to friends